DaVita Inc. DVA
Healthcare · Medical Care Facilities · United States · S&P 500
Based on the available data, DaVita Inc. gets an algorithmic score of 64/100. It trades at 175.19 $, with a sideways/transition technical trend (RSI 39.3) and 45.7% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (88.5%): generates strong profit on equity.
- Attractive free-cash-flow yield (11.7%).
- Low valuation (P/E 10.2).
- Low beta (0.38): defensive profile.
Weaknesses
- High leverage (debt/equity 1242%): rate-sensitive.
Fundamentals
| P/E | 15.08 |
| Forward P/E | 10.16 |
| PEG | 0.45 |
| P/B | -14.64 |
| EV/EBITDA | 9.11 |
| P/S | 0.80 |
| ROE % | 88.48 |
| ROA % | 7.51 |
| Gross margin % | 32.36 |
| Operating margin % | 16.06 |
| Net margin % | 6.05 |
| Revenue growth % (y/y) | 5.20 |
| Earnings growth % (y/y) | 55.80 |
| Revenue CAGR % | 5.53 |
| Earnings CAGR % | 10.04 |
| Debt/Equity % | 1,241.99 |
| Current ratio | 1.47 |
| FCF yield % | 11.66 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -3.0 % |
| 3 months | -21.3 % |
| 6 months | +15.0 % |
| YTD | +53.0 % |
| 1 year | +33.9 % |
| 3 years | +77.5 % |
| 5 years | +46.2 % |
Risk
| 1-year volatility | 45.7 % |
| Beta | 0.38 |
| 5-year max drawdown | -47.0 % |
| Sharpe 1A | 0.77 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.